宜明昂科生物医药技术（上海）股份有限公司（01541）于2025年12月4日发布2025年11月股份变动月报表。报告显示，公司本期在中国相关登记机关完成新增24,200,000股H股的注册手续，使注册股本从396,277,305股增至420,477,305股（均为每股面值人民币1.00元的H股）。
公司非上市股份仍维持11,030,390股不变。整体而言，截至2025年11月30日，公司注册股本总计人民币431,507,695元，对应431,507,695股，包括420,477,305股已上市流通的H股与11,030,390股非上市股份。
月报内容显示，2025年11月内公司并无额外的股份发行、购回、注销或库藏活动。公司亦未披露任何新期权或股权激励计划变动。截至本月底，已发行股份总数保持稳定，库存股份余额为零。
公告由执行董事、联席公司秘书关梅签署。公司方面确认已遵守香港联交所上市规则及相关法规。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.